Page 33 - AN-3-1

Advanced Neurology BTKi in brain diseases

mediated demyelination models of multiple sclerosis and 47. Traub J, Traffehn S, Ochs J, et al. Dimethyl fumarate impairs
neuromyelitis optica. Glia. 2018;66(12):2575-2588. differentiated B cells and fosters central nervous system
integrity in treatment of multiple sclerosis. Brain Pathol.
doi: 10.1002/glia.23512
2019;29(5):640-657.
38. Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus
interferon Beta-1a in relapsing multiple sclerosis. N Engl J doi: 10.1111/bpa.12711
Med. 2017;376(3):221-234. 48. Traub JW, Pellkofer HL, Grondey K, et al. Natalizumab
promotes activation and pro-inflammatory differentiation
doi: 10.1056/NEJMoa1601277
of peripheral B cells in multiple sclerosis patients. J
39. Barf T, Covey T, Izumi R, et al. Acalabrutinib (ACP-196): Neuroinflammation. 2019;16(1):228.
A covalent Bruton tyrosine kinase (BTK) inhibitor with
a differentiated selectivity and in vivo potency profile. J doi: 10.1186/s12974-019-1593-2
Pharmacol Exp Ther. 2017;363(2):240-252. 49. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion
with rituximab in relapsing-remitting multiple sclerosis. N
doi: 10.1124/jpet.117.242909
Engl J Med. 2008;358(7):676-688.
40. Rogers KA, Thompson PA, Allan JN, et al. Phase II study of
acalabrutinib in ibrutinib-intolerant patients with relapsed/ doi: 10.1056/NEJMoa0706383
refractory chronic lymphocytic leukemia. Haematologica. 50. Avouac A, Maarouf A, Stellmann JP, et al. Rituximab-induced
2021;106(9):2364-2373. hypogammaglobulinemia and infections in AQP4 and
MOG antibody-associated diseases. Neurol Neuroimmunol
doi: 10.3324/haematol.2020.272500
Neuroinflamm. 2021;8(3):e977.
41. Ng PY, Chang IS, Koh RY, Chye SM. Recent advances in tau-
directed immunotherapy against Alzheimer’s disease: An doi: 10.1212/NXI.0000000000000977
overview of pre-clinical and clinical development. Metab 51. Calderón-Parra J, Múñez-Rubio E, Fernández-Cruz A, et al.
Brain Dis. 2020;35(7):1049-1066. Incidence, clinical presentation, relapses and outcome of severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
doi: 10.1007/s11011-020-00591-6
infection in patients treated with anti-CD20 monoclonal
42. Reich D S, Arnold DL, Vermersch P, et al. Safety and efficacy antibodies. Clin Infect Dis. 2022;74(10):1786-1794.
of tolebrutinib, an oral brain-penetrant BTK inhibitor,
in relapsing multiple sclerosis: A phase 2b, randomised, doi: 10.1093/cid/ciab700
double-blind, placebo-controlled trial. Lancet Neurol. 52. Gaitzsch E, Passerini V, Khatamzas E, et al. COVID-19 in
2021;20(9):729-738. patients receiving CD20-depleting immunochemotherapy
for B-cell lymphoma. Hemasphere. 2021;5(7):e603.
doi: 10.1016/S1474-4422(21)00237-4
doi: 10.1097/HS9.0000000000000603
43. Crawford JJ, Johnson AR, Misner DL, et al. Discovery of
GDC-0853: A potent, selective, and noncovalent Bruton’s 53. Luna G, Alping P, Burman J, et al. Infection risks among
tyrosine kinase inhibitor in early clinical development. J patients with multiple sclerosis treated with fingolimod,
Med Chem. 2018;61(6):2227-2245. natalizumab, rituximab, and injectable therapies. JAMA
Neurol. 2020;77(2):184-191.
doi: 10.1021/acs.jmedchem.7b01712
doi: 10.1001/jamaneurol.2019.3365
44. Estupiñán HY, Berglöf A, Zain R Edvard Smith CI.
Comparative analysis of BTK inhibitors and mechanisms 54. Zecca C, Gobbi C. Long-term treatment with anti-CD20
underlying adverse effects. Front Cell Dev Biol. 2021;9:630942. monoclonal antibodies is untenable because of risk: YES.
Mult Scler. 2022;28(8):1173-1175.
doi: 10.3389/fcell.2021.630942
doi: 10.1177/13524585221088734
45. Xu W, Zhou K, Wang T, et al. Orelabrutinib in relapsed or
refractory chronic lymphocytic leukemia/small lymphocytic 55. Bar-Or A, Herman A, Stokmaier D. Author response:
lymphoma patients: Multi‐center, single‐arm, open‐label, Effect of ocrelizumab on vaccine responses in patients
phase 2 study. Am J Hematol. 2023;98(4):571-579. with multiple sclerosis: The VELOCE study. Neurology.
2021;96(18):870-872.
doi: 10.1002/ajh.26826
doi: 10.1212/WNL.0000000000011868
46. Benner B, Scarberry L, Stiff A, et al. Evidence for interaction
of the NLRP3 inflammasome and Bruton’s tyrosine kinase 56. Torke S, Pretzsch R, Häusler D, et al. Inhibition of
in tumor-associated macrophages: Implications for myeloid Bruton’s tyrosine kinase interferes with pathogenic B-cell
cell production of interleukin-1beta. Oncoimmunology. development in inflammatory CNS demyelinating disease.
2019;8(11):1659704. Acta Neuropathol. 2020;140(4):535-548.
doi: 10.1080/2162402x.2019.1659704 doi: 10.1007/s00401-020-02204-z

Volume 3 Issue 1 (2024) 9 https://doi.org/10.36922/an.2184